This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
Diamyd Medical AB (publ)
Q22024
3/27/2024
Interviewer
Host / Moderator
Welcome to this live interview with Diabyd Medical and their CEO Ulf Hanelius. This is due to the fact that they have released a report for the second quarter in the broken year 2023-2024. The period from December 1 to February 29. You who are watching can ask questions in the live chat and I have noticed that there were already a lot of questions before the broadcast. I turn to today's main person, Ulf Hanelius. Welcome. Thank you very much. How would you summarize the quarter in its entirety?
Ulf Hanelius
CEO of Diabyd Medical
In summary, it is an extremely positive quarter for Diabyd and it is with Fastrack that we got from FDA in February. We will go into this a little later, but it is and we have market analysis and everything else that has happened, so it is a truly positive quarter for Diabyd.
Interviewer
Host / Moderator
You will now be able to present a little, partly what you presented in Boston here this week. and tell us a little bit about the company's emissions, as you have announced. And then I'm back with some questions and then we can go into more detail. Yes, exactly. Then I say, please go ahead and start.
You're reading a preview of the DMYD-B.ST Q2 2024 earnings call.
Free account.
Disclaimer